Elevated C-reactive protein during hospitalization associated with increased mortality risk after recovery from COVID-19
Age, Higher Ferritin Levels Linked to More Severe MIS-C
Children aged 13 to 17 years, 6 to 12 years, with initial ferritin levels >500 µg/L had increased risk for ICU admission
SARS-CoV-2 Vaccination Seems Safe After MIS-C
No major adverse events seen among 15 children with MIS-C who were subsequently vaccinated against SARS-CoV-2
MIS-C Rare in 12- to 20-Year-Olds After COVID-19 Vaccination
Reporting rate was 1.0 case per million vaccinated individuals and 0.3 cases among those without evidence of SARS-CoV-2 infection
Cardiac Outcomes Good for Children With COVID-19-Related MIS-C
All deformation parameters on echocardiogram recovered within first week, including LV global longitudinal strain, peak left atrial strain
Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
COVID-19 Vaccines Significantly Cut MIS-C Risk in Teens
Of 107 children hospitalized with multisystem inflammatory syndrome in children, none were fully vaccinated
Study Characterizes Multisystem Inflammatory Syndrome in Adults
Review shows median age of 21 years, involvement of five organ systems, and presentation four weeks after COVID-19
mRNA COVID-19 Vaccines Immunogenic in Immunosuppressed Patients
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy